COVID-19 News

BARDA, MBio partner on serology test for COVID-19 antibodies

Dept. of Labor

The Biomedical Advanced Research and Development Authority (BARDA) and Boulder, Colorado-based MBio Diagnostics are committed to a public-private partnership to develop a test for COVID-19.

The MBio COVID-19 Serology Test is a rapid point-of-care serology test being designed to provide results in 5 minutes. This is a multiplexed cartridge-based lateral flow test that looks for anti-SARS-CoV-2 antibodies from active or past infections and allows on-site screening of people in non-professional settings such as a drive-thru setting or a walk-up testing site. The test also can assist in immunity assessment while broadening testing options.

The rapid point-of-care serology test will use MBio’s LightDeck® platform, and detect IgG (found in the blood and formed after infection) and IgM (formed while the body fights a new infection). The new test will quantify total antibody reactivity to three individual SARS-CoV-2 antigens which could provide critical data to aid in COVID-19 immunity assessment.

This is not MBio's first federal technology transfer agreement regarding COVID-19 treatment. The company has also developed a rapid, quantitative point-of-care test for the inflammatory protein interleukin-6 (IL-6), which will be used by researchers from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) in studies involving COVID-19 patients.

Read more:

Related news: